Bupropion, sold as Wellbutrin, is one of the least sedating antidepressants available. In a meta-analysis of second-generation antidepressants, bupropion actually caused drowsiness at a lower rate than placebo, while drugs like mirtazapine and fluvoxamine topped the sedation charts.1Journal of Clinical Psychopharmacology. Insomnia and Somnolence Associated With Second-Generation Antidepressants During the Treatment of Major Depression: A Meta-Analysis Yet a meaningful number of people who start Wellbutrin feel genuinely sleepy, and that experience is not imaginary. The disconnect between the clinical data and what some users feel has real explanations rooted in how the drug interacts with individual brain chemistry, liver enzymes, and even the formulation of the pill itself.
Bupropion’s Activating Profile and Why Sleepiness Feels Contradictory
Bupropion works primarily by blocking the reuptake of norepinephrine and dopamine, two neurotransmitters closely tied to wakefulness and motivation. It has no direct serotonergic activity, which is one reason it sidesteps the sedation, weight gain, and sexual side effects common with SSRIs and SNRIs.2PubMed Central. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor In head-to-head comparisons, bupropion improved excessive daytime sleepiness and fatigue more effectively than SSRIs. Among patients who achieved remission from depression, only about 20% on bupropion had lingering hypersomnia, compared to roughly 32% on SSRIs.3Biological Psychiatry. Resolution of Sleepiness and Fatigue in Major Depressive Disorder: A Comparison of Bupropion and the Selective Serotonin Reuptake Inhibitors
So the drug is, on average, energizing. That is exactly why feeling sleepy on it catches people off guard. The reasons someone bucks the trend fall into several categories, and most of them are specific to individual biology or dosing rather than a flaw in the drug’s overall design.
When Poor Sleep at Night Becomes Daytime Drowsiness
The most common reason people feel sleepy on Wellbutrin is not that the drug itself sedates them. It is that the drug disrupts their nighttime sleep, and the resulting sleep deprivation makes them drowsy the next day. This distinction matters, because the fix is very different for drug-induced insomnia versus true sedation.
A study comparing bupropion’s three formulations, immediate-release (IR), sustained-release (SR), and extended-release (XL), found that the IR version was linked to significantly higher daytime sleepiness scores than the other two formulations. The SR and XL versions did not differ from each other. The researchers attributed this to the IR formulation causing medication-induced insomnia at night, which then cascaded into next-day tiredness.4The Primary Care Companion for CNS Disorders. Development of Insomnia Associated With Different Formulations of Bupropion In other words, the pill was keeping people up at night so effectively that they felt exhausted during the day, and they interpreted that exhaustion as the drug making them sleepy.
This is consistent with bupropion’s classification as a disorder of arousal rather than sedation. The drug revs up the brain’s alertness circuitry. When that activation hits at the wrong time, especially with IR dosing in the afternoon or evening, you get insomnia followed by a rebound of fatigue the next morning. Switching to an XL formulation or moving the dose earlier in the day often resolves this pattern entirely.
How Your Liver Enzymes Shape the Experience
Bupropion is a prodrug in a meaningful sense: your liver converts it into several active metabolites, the most important being hydroxybupropion. This conversion is handled primarily by an enzyme called CYP2B6, and the gene coding for that enzyme varies substantially across people. How fast or slow your version of CYP2B6 works changes the balance between bupropion itself and hydroxybupropion in your bloodstream, and the two compounds have somewhat different pharmacological profiles.
A meta-analysis of studies on the CYP2B6*6 genetic variant found that carriers of this variant had roughly 23% lower exposure to hydroxybupropion compared to non-carriers.5PubMed. Association of CYP2B6 genetic polymorphisms with bupropion and hydroxybupropion exposure: A systematic review and meta-analysis Another study found that slow metabolizers produced hydroxybupropion at only about 34% of the rate seen in normal metabolizers.6PubMed Central. CYP2B6 and bupropion’s smoking cessation pharmacology: the role of hydroxybupropion A separate analysis pinpointed the CYP2B6*6 and *18 variants as being associated with about a 33% reduction in hydroxybupropion concentrations, with no corresponding change in bupropion levels themselves.7PubMed Central. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state
Why does this matter for sleepiness? Hydroxybupropion is the metabolite most strongly linked to clinical effects. If you are a slow metabolizer, you end up with more parent bupropion hanging around and less of the active metabolite doing the heavy lifting. The parent compound has its own receptor activity, including stronger effects at nicotinic acetylcholine receptors, which could shift the drug’s profile from activating toward something less stimulating or even mildly sedating in susceptible people. You would not know your CYP2B6 status unless you had pharmacogenomic testing, but it is one of the clearest biological explanations for why two people on the same dose of Wellbutrin can have such different experiences.
Nicotinic Receptor Blockade and Acetylcholine
One of bupropion’s less discussed actions is that it blocks nicotinic acetylcholine receptors. This is actually part of why the drug helps with smoking cessation: it interferes with the receptors that nicotine activates. Research has shown that bupropion is a noncompetitive antagonist at several nicotinic receptor subtypes, with particular potency at alpha3-beta2 and alpha4-beta2 receptors.8PubMed. Bupropion is a nicotinic antagonist
Acetylcholine is a major player in maintaining wakefulness and attention. It is the neurotransmitter that the brain’s cholinergic system uses to keep you alert, and drugs that block it tend to cause drowsiness. Think of antihistamines like diphenhydramine, which are sedating partly because they also block acetylcholine signaling. Bupropion’s nicotinic blockade is not nearly as broad or potent as a classic anticholinergic drug, but in people whose cholinergic systems are already running low or who are sensitive to disruptions in that pathway, even moderate interference could tip the balance toward sleepiness.
This mechanism may be especially relevant in the first week or two of treatment, before the brain adjusts to the new receptor environment. It also helps explain why the tiredness some people feel on Wellbutrin has a distinctive quality: not the heavy, druggy sedation of a serotonergic antidepressant, but more of a foggy, mentally drained feeling, as if the brain’s alertness signal has been turned down a notch.
The Paradoxical Calming Effect of Dopamine Stimulation
Here is where things get counterintuitive. In some individuals, increasing dopamine transmission in the brain does not produce the expected boost in energy and motivation. Instead, it has a calming or even sedating effect. This paradoxical response has been well-documented in research on ADHD, where stimulant medications that increase dopamine often reduce hyperactivity rather than amplifying it.
Animal studies have shown that bupropion, along with other dopamine-boosting drugs, can reverse motor hyperactivity in models with disrupted dopamine transporter function. The mechanism appears to involve a specific signaling cascade in the striatum, a brain region critical for movement and reward, where increased dopamine triggers a chain of events that paradoxically quiets overactive circuits.9PubMed Central. Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine Related research has demonstrated that increasing dopamine availability in the prefrontal cortex can reduce hyperactivity even when the dopamine boost comes from indirect pathways.10Scientific Reports. A role for cortical dopamine in the paradoxical calming effects of psychostimulants
For someone whose baseline dopamine signaling is atypical, whether due to ADHD, chronic stress, or simply natural variation, bupropion’s dopamine boost could produce a settling, calming sensation that gets experienced as tiredness. This is not the drug malfunctioning. It is the drug normalizing a system that was previously in overdrive, and the transition from a revved-up state to a calmer one can feel like the energy has been drained. People with undiagnosed or subclinical ADHD sometimes notice this effect particularly strongly when they start Wellbutrin.
What Bupropion Does to Your Sleep Stages
Even when bupropion does not cause obvious insomnia, it subtly reshapes sleep architecture in ways that could leave you feeling less rested. The most consistent finding in sleep studies is that bupropion increases REM latency, meaning it pushes the first episode of REM sleep later into the night.11PubMed Central. Bupropion response on sleep quality in patients with depression: implications for increased cardiovascular disease risk One study found that this REM latency shift was actually a marker for whether the drug would work: patients who responded well to bupropion showed increased REM latency, while non-responders showed the opposite pattern.12PubMed. Effect of bupropion-SR on REM sleep: relationship to antidepressant response
REM sleep is involved in emotional processing, memory consolidation, and subjective feelings of having slept well. Delaying it does not necessarily reduce total REM time, but it changes when and how REM episodes are distributed across the night. For some people, particularly those who were already getting fragmented REM sleep due to depression, this shift can produce mornings where they feel like they slept without truly resting. The resulting grogginess is easy to mistake for sedation caused by the drug, when it is really a side effect of altered sleep quality that may improve as the brain adapts over the first few weeks.
Drug Interactions That Amplify Sedation
Bupropion is a moderate inhibitor of the CYP2D6 enzyme, which metabolizes a wide range of other medications.13PubMed. Clinically significant drug interactions with newer antidepressants If you are taking another drug that relies on CYP2D6 for clearance, adding Wellbutrin can slow the breakdown of that second drug, effectively raising its blood levels. When the second drug happens to be sedating, such as certain antihistamines, beta-blockers, opioids, or other psychiatric medications, the result is more sleepiness than you would get from either drug alone.
This interaction is easy to overlook because neither the prescriber nor the patient may be thinking about enzyme inhibition. The sleepiness gets blamed on Wellbutrin, when in reality Wellbutrin is amplifying the sedating effects of something else in the medication regimen. This is particularly relevant for people on multiple medications, which is common in treatment-resistant depression. If you start Wellbutrin and notice drowsiness, it is worth checking whether any of your other medications are CYP2D6 substrates.
Unmasking Fatigue That Was Always There
Depression itself often masks its own symptoms through a kind of anxious arousal. Many people with depression run on a cocktail of stress hormones and rumination-driven insomnia that creates a wired-but-tired state. They are exhausted underneath, but the mental agitation keeps them from feeling it fully. When an antidepressant begins to work and the anxiety and rumination dial down, the underlying exhaustion comes forward.
Bupropion improves fatigue and hypersomnia more effectively than SSRIs over the course of treatment, but the early weeks can be a different story.3Biological Psychiatry. Resolution of Sleepiness and Fatigue in Major Depressive Disorder: A Comparison of Bupropion and the Selective Serotonin Reuptake Inhibitors As the drug starts modulating norepinephrine and dopamine, the anxious edge may soften before the energizing effects fully kick in. During that transitional window, the fatigue that was always lurking beneath the agitation finally becomes perceptible. Patients interpret this as the drug causing sleepiness, when the drug is actually revealing a deficit that was being papered over by the illness.
This effect is temporary for most people. As bupropion reaches steady state, usually within a couple of weeks, and as its antidepressant effects deepen, energy levels typically rise. The early-phase sleepiness is one of the more common reasons people abandon the drug prematurely, which is unfortunate given that bupropion’s long-term track record for resolving fatigue is among the best of any antidepressant.
Indirect Serotonergic Effects at Higher Doses
Although bupropion is classified as having no direct serotonergic activity, the picture is not entirely clean. Case reports and pharmacological analyses have documented serotonin syndrome occurring with bupropion as the sole agent, which should be impossible for a drug with zero serotonin involvement. The proposed explanation is that bupropion can indirectly increase serotonergic cell activity, likely through its effects on other neurotransmitter systems that modulate serotonin circuits.14The Journal of Emergency Medicine. Two Cases of Serotonin Syndrome After Bupropion Overdose Treated With Cyproheptadine
This indirect serotonin boost is unlikely to be a major player at standard therapeutic doses, but in overdose situations or in people who are genetically predisposed to higher serotonin tone, it could contribute to a sedating quality that you would not expect from the drug’s official pharmacological profile. It also raises the possibility that bupropion combined with even mild serotonergic agents, like certain supplements or foods, could push serotonin signaling high enough to produce drowsiness in sensitive individuals.
Bupropion’s Effects on Inflammation
An emerging area of research connects antidepressant effects to immune modulation, and bupropion has shown some interesting inflammatory properties. In animal studies, bupropion reduced key pro-inflammatory molecules like TNF-alpha and interferon-gamma while increasing the anti-inflammatory cytokine IL-10.15International Immunopharmacology. A new chapter opens in anti-inflammatory treatments: The antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice A human study in men with major depression found that four weeks of bupropion treatment significantly shifted cytokine profiles, increasing both pro-inflammatory and anti-inflammatory markers but with the anti-inflammatory side appearing to dominate the net effect.16Journal of Medical Sciences. Bupropion Associated Immunomodulatory Effects on Peripheral Cytokines in Male with Major Depressive Disorder
The relevance to sleepiness is speculative but plausible. Immune activation is closely tied to the “sickness behavior” response, which includes fatigue and sleepiness as core features. If bupropion causes a transient immune recalibration during the early weeks of treatment, particularly increasing certain cytokines before the anti-inflammatory effects predominate, that immune shift could contribute to a temporary period of feeling tired. Cell culture experiments have hinted that bupropion’s immune effects are complex and dose-dependent, with some concentrations showing pro-inflammatory patterns.17Inflammopharmacology. Revisiting bupropion anti-inflammatory action: involvement of the TLR2/TLR4 and JAK2/STAT3 The science here is still early, but it adds another potential pathway for the fatigue some people report.
Formulation Differences and Bioavailability
Not all Wellbutrin pills deliver bupropion the same way, and the differences matter more than most people realize. The three main formulations, IR, SR, and XL, differ in how quickly and how much active drug reaches your bloodstream at any given time. A pharmacokinetic study comparing the three found that the extended-release formulations had a relative bioavailability of roughly 72 to 79% compared to the immediate-release version, meaning the slower-release pills deliver less of the drug per unit time.18The AAPS Journal. Pharmacokinetics and Pharmacogenomics of Bupropion in Three Different Formulations with Different Release Kinetics in Healthy Human Volunteers The ratio of metabolites to parent drug stayed the same across formulations, so the difference is about timing and peak levels, not about which metabolites you make.
The IR formulation produces sharp peaks and troughs in blood levels throughout the day. Those peaks can cause agitation and insomnia, while the troughs can bring a crash that feels like sedation. The XL version smooths this out into a more even curve. If you are experiencing cycles of jitteriness followed by sleepiness, the formulation may be a bigger factor than the drug itself. Generic extended-release versions have also come under scrutiny in the past for varying dissolution profiles, though current FDA-approved generics are required to meet bioequivalence standards.
Bipolar Disorder and Mood-State Shifts
For people with bipolar disorder, the question of sleepiness on bupropion takes on a different dimension. If bupropion triggers a shift into a depressive phase, the resulting low mood and fatigue could easily be attributed to the drug causing sedation when the real issue is a mood episode. A meta-analysis examining bupropion’s risk of causing mood switches in bipolar patients found no significant difference in phase-shifting rates between bupropion and other antidepressants, including SSRIs and SNRIs.19PubMed Central. Significant Treatment Effect of Bupropion in Patients With Bipolar Disorder but Similar Phase-Shifting Rate as Other Antidepressants: A Meta-Analysis Following the PRISMA Guidelines Bupropion is often considered one of the safer antidepressant choices in bipolar disorder for this reason, but the risk is not zero. Anyone with bipolar disorder who becomes sleepy on Wellbutrin should consider whether they are entering a depressive swing rather than assuming the drug itself is sedating.
This also applies more broadly to unipolar depression that features pronounced fatigue as a core symptom. If the antidepressant does not adequately treat the depressive fatigue, or if the depression worsens before it improves, the residual symptom of sleepiness can be misattributed to the medication rather than the illness. Distinguishing drug side effects from disease symptoms is one of the trickier problems in psychiatric treatment, and bupropion’s reputation as an activating drug makes it even harder: both the patient and the clinician may assume that sleepiness cannot possibly be from the depression if the person is on an energizing medication.